1250 / 1851
DAHANCA 19: ART only, oropharynx, HPV/p16+
Pts. at risk Events
zalutumumab 24
6
control
29
3
total
53
9
control 89%
zalutumumab 76%
HR: 2.19 [95% CI: 0.55-8.77]
Pts. at risk Events
zalutumumab 24
7
control
29
5
total
53
12
control 80%
zalutumumab 74%
HR: 1.36 [95% CI: 0.42-4.46]
Loco-regional control
Overall survival
Eriksen 2015